BioAegis’ Patent Coverage Expands to Asia
Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria and this broad patent filing was recently granted in China. BioAegis is pursuing worldwide patent filings for infectious disease.
September 26, 2012: Broad Infectious Disease Patent Issued in China for Plasma Gelsolin
- September 26, 2012